Stock Comparison

ABBV vs ECOR

AbbVie Inc vs electroCore, Inc.

The Verdict

ECOR takes this one.

ABBV

AbbVie Inc

0.1

out of 10

Distressed

Winner

ECOR

electroCore, Inc.

2.5

out of 10

Risk Trap

Head-to-Head

$381.1B

Market Cap

$79M

104.8

P/E Ratio

N/A

5.8%

Profit Margin

-44.1%

95.6%

Return on Equity

-235.8%

20.2

Debt-to-Equity

N/A

Moderate

Overall Risk

Aggressive

0.1

DVR Score

2.5

The Deep Dive

ABBV0.1/10

AbbVie (ABBV) remains a well-established mega-cap pharmaceutical company, demonstrating stable, incremental growth driven by its robust immunology portfolio, notably Skyrizi and Rinvoq. Q1 2026 results showed modest revenue and adjusted EPS growth, with slightly raised full-year guidance. While financially healthy and a strong dividend payer, its immense market capitalization ($381.10B) and the ma...

Full ABBV Analysis

ECOR2.5/10

electroCore exhibits strong operational execution, evidenced by Q1 2026 revenue of $9.6M, representing a 42.64% YoY increase, and its gammaCore device addresses a vast market for headache disorders with patented, non-invasive technology. This market potential and product strength are compelling. However, these positives are severely undermined by critical financial distress. The company faces pers...

Full ECOR Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.